Sentimag® - Magtrace® in breast cancer

Many treatments for early-stage breast cancer involve sentinel lymph node biopsy (SLNB). This method, which identifies the lymph nodes with the highest potential for harbouring metastases, helps to determine the nodal stage of the cancer and make informed decisions for surgery and subsequent treatment.

Standard SLNB uses radioisotopes for sentinel node localisation. We offer an effective clinical solution that uses safe magnetic fields instead. This eliminates concerns related to issues of safety, workflow and availability associated with ionising radiation. Best practice SLNB is now possible everywhere, with no time restrictions.

Our system consists of the Sentimag^® probe and the Magtrace^® magnetic tracer. First, the tracer is injected into the interstitial tissue to provide a traceable signal. Next, using the Sentimag^® probe, the sentinel lymph nodes are located to determine how far the cancer has spread.

Magtrace^® – An effective clinical solution

• Perform best practice SLNB in any clinical setting
• Eliminate issues with radioactive materials; reach equivalent clinical outcomes
• As a surgeon, organise and manage the SLNB procedure to suit your needs
• Inject the tracer at the most convenient time, up to seven days in advance
• No evidence of anaphylaxis with interstitial tracer injection
• Sentimag^® and Magtrace^® are CE-approved for SLN localisation

Endomag^®, Sentimag^®, Magseed^® and Sienna+^® are registered European Union trademarks of Endomagnetics Ltd · www.endomag.com
Magtrace^® is a registered trademark of Endomagnetics Ltd in the United Kingdom · www.endomag.com

Product documents

Regulatory documents

Regulatory documents, such as Instructions for Use, can be accessed with a valid My Sysmex login: